Hospitals Network Articles & Analysis
36 news found
It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma ...
This data also provides tremendous value back to hospital partners and clinicians as Caresyntax provides data science reporting and analysis back to hospitals for their value analysis, product evaluation, and value-based care initiatives. ...
We look forward to sharing more site contact information with patients and their clinicians in the future as we activate more sites and some of the largest oncology networks in the US and Europe, making Flamingo-01 available to as many patients as ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: As previously disclosed, clinical trial contracts and budgets have been executed at multiple hospitals and the ...
This contract was awarded based on the recommendation of Early Bird by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the health care industry. ...
In 2021, the ActivSight imaging module was cleared by the FDA and successfully used in its first-in-human studies. To date, multiple major hospital networks across the U.S. and Europe have been established as pilot sites. ...
Aidoc’s AI platform is currently used by hospitals, health networks and radiology groups worldwide across multiple service lines. ...
ByAidoc
At least 25 sites are currently in the study start-up process at a variety of university-based hospitals and cooperative networks. Industry leaders for the Phase III clinical trial’s Data Safety Monitoring Board have been recruited and the Steering Committee members are being confirmed. ...
“We’re proud to partner with a leading, innovative hospital network like Novant Health, which serves a large portion of the population in the three states its facilities are located in. ...
ByAidoc
” About the DA01 Phase 1 Trial In Canada, the trial is being conducted in partnership with University Health Network, Canada’s largest research and teaching hospital network, located in Toronto, Ontario under the guidance of Dr. ...
” According to a 2021 survey of U.S. hospitals, 90 percent have an AI strategy in place—up from 53 percent in 2019—yet implementation lags behind with only 34 percent deploying an AI solution. ...
ByAidoc
” The idea for this probe was born and developed in Quebec and, as it goes through various medical and regulatory tests, has put the province at the centre of an increasingly international network of hospitals that will test the device. Preliminary results have been positive, making this a story where an enterprising Quebec company, founded by local ...
By providing remote access to the full range of conditions monitored by PeriWatch Vigilance, the new solution empowers obstetricians and nursing leaders to actively monitor hours of real-time Electronic Fetal Monitoring (EFM) and maternal vital signs for multiple patients––from anywhere they can access the hospital network through ...
Vizient’s diverse customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and nonacute health care providers, representing more than $110 billion in annual purchasing volume. ...
Specific Diagnostics today announced results from two studies conducted in the Paris Teaching Hospital System (Assistance Publique-Hôpitaux Paris, AP-HP), Europe’s largest hospital network, reporting performance of the Reveal rapid antibiotic susceptibility testing (AST) system. ...
University Hospitals Leuven, KU Leuven and BioXtreme are proud to announce that they have agreed to conduct a joint clinical trial research project in the university’s facility in Leuven, Belgium. ...